Methimazole in the Treatment of Melasma: A Clinical and Dermascopic Study

Methimazole in the Treatment of Melasma: A Clinical and Dermascopic Study

BACKGROUND: Melasma is a chronic hypermelanotic disorder that is challenging to treat; no single effective therapeutic agent for it has been discovered. Methimazole, an oral antithyroid drug, has a skin depigmenting effect when used topically. OBJECTIVE: We sought to evaluate the efficacy and safety...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of clinical and aesthetic dermatology 2021-02, Vol.14 (2), p.14-20
Hauptverfasser: Farag, Azza, Hammam, Mostafa, Alnaidany, Nada, Badr, Eman, Elshaib, Mustafa, El-Swah, Aliaa, Shehata, Wafaa
Format: Artikel
Sprache:eng
Schlagworte:
Original Research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 20
container_issue 2
container_start_page 14
container_title The Journal of clinical and aesthetic dermatology
container_volume 14
creator Farag, Azza
Hammam, Mostafa
Alnaidany, Nada
Badr, Eman
Elshaib, Mustafa
El-Swah, Aliaa
Shehata, Wafaa
description BACKGROUND: Melasma is a chronic hypermelanotic disorder that is challenging to treat; no single effective therapeutic agent for it has been discovered. Methimazole, an oral antithyroid drug, has a skin depigmenting effect when used topically. OBJECTIVE: We sought to evaluate the efficacy and safety of methimazole, applied during microneedling sessions and additional topical use in between sessions, for the treatment of melasma. METHODS: This split-face study included 30 Egyptian patients with melasma, each of whom received 12 microneedling sessions once per week for 12 weeks followed by topical methimazole on the right side of face and placebo on the left side. In between the sessions, topical methimazole 5% cream was applied twice per day on the right side and placebo on the left side. Assessments were performed using the Hemi-melasma Area and Severity Index (hemi-MASI) percentage of improvement, patient satisfaction, dermoscopy, and thyroid-stimulating hormone (TSH) serum levels. RESULTS: There were significant clinical and dermoscopic improvements; hemi-MASI scores on the methimazole-treated right sides were decreased ( p
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8211339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2548628640</sourcerecordid><originalsourceid>FETCH-LOGICAL-p158t-73967dc0acc7e7440c27cc7fc9435a65a8a6b05f3a3a8ad8edff7796f6b48f1a3</originalsourceid><addsrcrecordid>eNpVj0tLAzEcxIMottR-hxy9LGzeiQeh1FehxYP1HP7NJjaSfbjZFeqnd8FenMsMDPyYuUBzKrUpDFHiEs2J4aSgSpsZWub8WU5i2gjFr9GMcUoJpXSONjs_HGMNP23yODZ4OHq87z0MtW8G3Aa88wlyDXd4hdcpNtFBwtBU-MH3NWTXdtHht2GsTjfoKkDKfnn2BXp_etyvX4rt6_NmvdoWHRF6KBQzUlWuBOeUV5yXjqopBmc4EyAFaJCHUgQGbIqV9lUIShkZ5IHrQIAt0P0ftxsPta_ctLOHZLt-etGfbAvR_m-aeLQf7bfVlBDGzAS4PQP69mv0ebB1zM6nBI1vx2yp4FpSLXnJfgGxQGU2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548628640</pqid></control><display><type>article</type><title>Methimazole in the Treatment of Melasma: A Clinical and Dermascopic Study</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Farag, Azza ; Hammam, Mostafa ; Alnaidany, Nada ; Badr, Eman ; Elshaib, Mustafa ; El-Swah, Aliaa ; Shehata, Wafaa</creator><creatorcontrib>Farag, Azza ; Hammam, Mostafa ; Alnaidany, Nada ; Badr, Eman ; Elshaib, Mustafa ; El-Swah, Aliaa ; Shehata, Wafaa</creatorcontrib><description>BACKGROUND: Melasma is a chronic hypermelanotic disorder that is challenging to treat; no single effective therapeutic agent for it has been discovered. Methimazole, an oral antithyroid drug, has a skin depigmenting effect when used topically. OBJECTIVE: We sought to evaluate the efficacy and safety of methimazole, applied during microneedling sessions and additional topical use in between sessions, for the treatment of melasma. METHODS: This split-face study included 30 Egyptian patients with melasma, each of whom received 12 microneedling sessions once per week for 12 weeks followed by topical methimazole on the right side of face and placebo on the left side. In between the sessions, topical methimazole 5% cream was applied twice per day on the right side and placebo on the left side. Assessments were performed using the Hemi-melasma Area and Severity Index (hemi-MASI) percentage of improvement, patient satisfaction, dermoscopy, and thyroid-stimulating hormone (TSH) serum levels. RESULTS: There were significant clinical and dermoscopic improvements; hemi-MASI scores on the methimazole-treated right sides were decreased ( p &lt;0.001). The percent of hemi-MASI score improvement was significantly associated with the malar pattern ( p =0.031) and epidermal type ( p =0.04) of melasma. About 70 percent of our studied patients reported being satisfied with their treatment response (7% excellent, 33% good, 30% fair). No significant local or systemic side effects were observed. Pre- and posttreatment serum TSH levels were within the normal range in all treated cases. CONCLUSIONS: Methimazole has the potential to be a safe and promising therapeutic agent for the treatment of melasma via dermapen-delivered microneedling sessions with topical use in between sessions.</description><identifier>ISSN: 1941-2789</identifier><identifier>EISSN: 2689-9175</identifier><identifier>PMID: 34221222</identifier><language>eng</language><publisher>Matrix Medical Communications</publisher><subject>Original Research</subject><ispartof>The Journal of clinical and aesthetic dermatology, 2021-02, Vol.14 (2), p.14-20</ispartof><rights>Copyright © 2021. Matrix Medical Communications. All rights reserved. 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211339/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211339/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids></links><search><creatorcontrib>Farag, Azza</creatorcontrib><creatorcontrib>Hammam, Mostafa</creatorcontrib><creatorcontrib>Alnaidany, Nada</creatorcontrib><creatorcontrib>Badr, Eman</creatorcontrib><creatorcontrib>Elshaib, Mustafa</creatorcontrib><creatorcontrib>El-Swah, Aliaa</creatorcontrib><creatorcontrib>Shehata, Wafaa</creatorcontrib><title>Methimazole in the Treatment of Melasma: A Clinical and Dermascopic Study</title><title>The Journal of clinical and aesthetic dermatology</title><description>BACKGROUND: Melasma is a chronic hypermelanotic disorder that is challenging to treat; no single effective therapeutic agent for it has been discovered. Methimazole, an oral antithyroid drug, has a skin depigmenting effect when used topically. OBJECTIVE: We sought to evaluate the efficacy and safety of methimazole, applied during microneedling sessions and additional topical use in between sessions, for the treatment of melasma. METHODS: This split-face study included 30 Egyptian patients with melasma, each of whom received 12 microneedling sessions once per week for 12 weeks followed by topical methimazole on the right side of face and placebo on the left side. In between the sessions, topical methimazole 5% cream was applied twice per day on the right side and placebo on the left side. Assessments were performed using the Hemi-melasma Area and Severity Index (hemi-MASI) percentage of improvement, patient satisfaction, dermoscopy, and thyroid-stimulating hormone (TSH) serum levels. RESULTS: There were significant clinical and dermoscopic improvements; hemi-MASI scores on the methimazole-treated right sides were decreased ( p &lt;0.001). The percent of hemi-MASI score improvement was significantly associated with the malar pattern ( p =0.031) and epidermal type ( p =0.04) of melasma. About 70 percent of our studied patients reported being satisfied with their treatment response (7% excellent, 33% good, 30% fair). No significant local or systemic side effects were observed. Pre- and posttreatment serum TSH levels were within the normal range in all treated cases. CONCLUSIONS: Methimazole has the potential to be a safe and promising therapeutic agent for the treatment of melasma via dermapen-delivered microneedling sessions with topical use in between sessions.</description><subject>Original Research</subject><issn>1941-2789</issn><issn>2689-9175</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVj0tLAzEcxIMottR-hxy9LGzeiQeh1FehxYP1HP7NJjaSfbjZFeqnd8FenMsMDPyYuUBzKrUpDFHiEs2J4aSgSpsZWub8WU5i2gjFr9GMcUoJpXSONjs_HGMNP23yODZ4OHq87z0MtW8G3Aa88wlyDXd4hdcpNtFBwtBU-MH3NWTXdtHht2GsTjfoKkDKfnn2BXp_etyvX4rt6_NmvdoWHRF6KBQzUlWuBOeUV5yXjqopBmc4EyAFaJCHUgQGbIqV9lUIShkZ5IHrQIAt0P0ftxsPta_ctLOHZLt-etGfbAvR_m-aeLQf7bfVlBDGzAS4PQP69mv0ebB1zM6nBI1vx2yp4FpSLXnJfgGxQGU2</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Farag, Azza</creator><creator>Hammam, Mostafa</creator><creator>Alnaidany, Nada</creator><creator>Badr, Eman</creator><creator>Elshaib, Mustafa</creator><creator>El-Swah, Aliaa</creator><creator>Shehata, Wafaa</creator><general>Matrix Medical Communications</general><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210201</creationdate><title>Methimazole in the Treatment of Melasma: A Clinical and Dermascopic Study</title><author>Farag, Azza ; Hammam, Mostafa ; Alnaidany, Nada ; Badr, Eman ; Elshaib, Mustafa ; El-Swah, Aliaa ; Shehata, Wafaa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p158t-73967dc0acc7e7440c27cc7fc9435a65a8a6b05f3a3a8ad8edff7796f6b48f1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Original Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farag, Azza</creatorcontrib><creatorcontrib>Hammam, Mostafa</creatorcontrib><creatorcontrib>Alnaidany, Nada</creatorcontrib><creatorcontrib>Badr, Eman</creatorcontrib><creatorcontrib>Elshaib, Mustafa</creatorcontrib><creatorcontrib>El-Swah, Aliaa</creatorcontrib><creatorcontrib>Shehata, Wafaa</creatorcontrib><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical and aesthetic dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farag, Azza</au><au>Hammam, Mostafa</au><au>Alnaidany, Nada</au><au>Badr, Eman</au><au>Elshaib, Mustafa</au><au>El-Swah, Aliaa</au><au>Shehata, Wafaa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methimazole in the Treatment of Melasma: A Clinical and Dermascopic Study</atitle><jtitle>The Journal of clinical and aesthetic dermatology</jtitle><date>2021-02-01</date><risdate>2021</risdate><volume>14</volume><issue>2</issue><spage>14</spage><epage>20</epage><pages>14-20</pages><issn>1941-2789</issn><eissn>2689-9175</eissn><abstract>BACKGROUND: Melasma is a chronic hypermelanotic disorder that is challenging to treat; no single effective therapeutic agent for it has been discovered. Methimazole, an oral antithyroid drug, has a skin depigmenting effect when used topically. OBJECTIVE: We sought to evaluate the efficacy and safety of methimazole, applied during microneedling sessions and additional topical use in between sessions, for the treatment of melasma. METHODS: This split-face study included 30 Egyptian patients with melasma, each of whom received 12 microneedling sessions once per week for 12 weeks followed by topical methimazole on the right side of face and placebo on the left side. In between the sessions, topical methimazole 5% cream was applied twice per day on the right side and placebo on the left side. Assessments were performed using the Hemi-melasma Area and Severity Index (hemi-MASI) percentage of improvement, patient satisfaction, dermoscopy, and thyroid-stimulating hormone (TSH) serum levels. RESULTS: There were significant clinical and dermoscopic improvements; hemi-MASI scores on the methimazole-treated right sides were decreased ( p &lt;0.001). The percent of hemi-MASI score improvement was significantly associated with the malar pattern ( p =0.031) and epidermal type ( p =0.04) of melasma. About 70 percent of our studied patients reported being satisfied with their treatment response (7% excellent, 33% good, 30% fair). No significant local or systemic side effects were observed. Pre- and posttreatment serum TSH levels were within the normal range in all treated cases. CONCLUSIONS: Methimazole has the potential to be a safe and promising therapeutic agent for the treatment of melasma via dermapen-delivered microneedling sessions with topical use in between sessions.</abstract><pub>Matrix Medical Communications</pub><pmid>34221222</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1941-2789
ispartof The Journal of clinical and aesthetic dermatology, 2021-02, Vol.14 (2), p.14-20
issn 1941-2789
2689-9175
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8211339
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Original Research
title Methimazole in the Treatment of Melasma: A Clinical and Dermascopic Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A11%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methimazole%20in%20the%20Treatment%20of%20Melasma:%20A%20Clinical%20and%20Dermascopic%20Study&rft.jtitle=The%20Journal%20of%20clinical%20and%20aesthetic%20dermatology&rft.au=Farag,%20Azza&rft.date=2021-02-01&rft.volume=14&rft.issue=2&rft.spage=14&rft.epage=20&rft.pages=14-20&rft.issn=1941-2789&rft.eissn=2689-9175&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2548628640%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548628640&rft_id=info:pmid/34221222&rfr_iscdi=true